Michael I. Okkonen


Michael I. Okkonen


Brussels | 480 Avenue Louise, Box 13A, Brussels 1050
+32 2 535 5416 | +32 2 535 5400

| vCard | PDF

Michael I. Okkonen focuses his practice on all aspects of EU competition law, with a particular focus on cartel and abuse of dominance matters, and complex merger control proceedings.

Mr. Okkonen has experience advising clients in sectors such as chemicals, consumer products, manufacturing and pharmaceuticals.

Prior to joining the Brussels team, Mr. Okkonen completed a traineeship at the European Commission (DG Competition) in an Antitrust unit working on Pharmaceuticals. He has also completed an internship in a Finnish law firm focusing on EU law matters, in particular, the four free movements.

Mr. Okkonen regularly publishes on competition law topics.

  • Cathay Capital on its Investment in Cenexi Group.
  • Cerberus and PaxVax on Sale of PaxVax to Emergent BioSolutions for US$270 million.
  • Court Square Capital Partners on its investment in Getaroom.
  • Differential Brands Group Inc.’s acquisition of Global Brands Group’s North American Division for US$1.38 billion.
  • Ipsen in its acquisition of the global oncology assets of Merrimack Pharmaceuticals, including its key marketed product ONIVYDE®, for up to US$1 billion. 
  • J.H. Whitney in various acquisitions.
  • Kofax on US$1 billion sale to Lexmark.
  • Lazada on US$1 billion sale to Alibaba.
  • M1 Fashion and L Capital Asia on Pepe Jeans Group Acquisition before the EU Commission.
  • MSD Partners in its acquisition of Hayward Industries in Partnership with CCMP Capital Advisors, Alberta Investment Management Corp. and Ring Container Technologies.
  • OCI Enterprises Inc. in sale of OCI Resources LP Interests to Park Holding A.S. of Ciner Group.
  • Ritchie Bros. on US$758.5 million Acquisition of IronPlanet.
  • Shanghai Shenda in Formation of Joint Venture with IAC in Automotive Soft Trim and Acoustics Supply Business
  • Tech Mahindra on US$240 Million Acquisition of Lightbridge Communications Corporation.
  • A major US pharmaceutical supplier against a takeover by another US pharmaceutical company.


  • University of Warwick, LL.B. Law (Hons), 2008
  • College of Law, Legal Practice Course, 2009
  • College of Europe, LL.M., European Legal Studies, 2012
  • King’s College London, Postgraduate Diploma in Legal Practice, Economics in Competition Law, 2017
  • England and Wales
  • New York
  • Brussels (RFL)
  • English
  • French
  • Russian
  • Finnish
  • Spanish